Press release
Releases New Report on the Global Primary Biliary Cholangitis (PBC) Treatment Market
Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally diagnosed during routine blood examination which presents symptoms like fatigue, pertussis, and right upper quadrant discomfort. In initial examination finding the disease is normal, as the disease advances present symptoms of liver cirrhosis. The hallmark of primary biliary cirrhosis is the presence of antimitochondrial antibodies (AMAs) in the blood. Medical management of primary biliary cirrhosis mainly done to slow the symptom progression and to alleviate the symptoms.Primary Biliary Cholangitis Treatment Market: Drivers and Restraints
Global primary biliary cholangitis treatment market is expected to drive by highly unmet medical need owing lack of definitive treatment, advanced diagnostic process coupled rising awareness among healthcare professionals and patients alike across the globe. The Incidence and prevalence of primary biliary cholangitis vary geographically, ranging from 0.7 to 49 and 6.7 to 402 per million, respectively. The factors currently contributing to the revenue growth of the primary biliary cholangitis treatment market is increasing incidence and prevalence of the disease, increased exposure to environmental triggers to immune system such as pesticides. Furthermore, lifestyle changes like smoking, alcoholism, and obesity are expected to drive the market for primary biliary cholangitis treatment over the forecast period.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3773
Global primary biliary cholangitis treatment market hindered by the lack of definitive treatment for the disease and late diagnosis of the disease led to treatment deprivation to the patient. The market restrained by dearth of epidemiology data which helps to assess the product access and availability in various geographies which are expected to hinder market revenue growth of primary biliary cholangitis treatment over the forecast period
Primary Biliary Cholangitis Treatment Market: Segmentation
Global primary biliary cholangitis treatment market has been segmented on the basis of treatment type, end user and Region.
Based on the treatmenttype, the global primary biliary cholangitis treatment market is segmented into the following:
For Treatment
Ursodeoxycholic acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
For Symptom Control
Antihistamines
Cholestyramine
Antibacterials
Opioid Antagonists
Colestipol
Others
Based on the end user, the global primary biliary cholangitis treatment market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Primary Biliary Cholangitis Treatment Market: Overview
Global primary biliary cholangitis treatment market is witnessing significant changes due to recent approval of UDCA by several regulatory authorities across the globe. In May 2016, the FDA approved obeticholic acid in combination with UDCA for primary biliary cholangitis (PBC) in adult patients with an inadequate response to UDCA. U.K’s NICE (National Institute for Health and Care Excellence) and European Commission granted the market authorization for Ocaliva (obeticholic acid) form Intercept Pharmaceuticals, Inc. in the year 2017 and 2016 respectively.
Primary Biliary Cholangitis Treatment Market: Region-wise Outlook
Geographically, Primary biliary cholangitis treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Western Europe will remain key markets for primary biliary cholangitis treatment products due to increased regulatory approvals for treatment options, increasing awareness among patient advocacy groups regarding primary biliary cholangitis helps to maintain larger market share in the globalprimary biliary cholangitis treatment market by the regions. Asia Pacific is anticipated to present better growth opportunity owing to large untapped market, increasing out of pocket expenditure, and growing government’s interventions for improving healthcare infrastructure in the region.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3773
Primary Biliary Cholangitis Treatment Market: Key Players
Some of the players in the global primary biliary cholangitis treatment market are Intercept Pharmaceuticals, Inc., Actavis, Inc., Teva Pharmaceuticals Inc., Epic Pharma, LLC, Mylan Pharmaceuticals Inc., and Axcan Scandipharm Inc. to name a few.
About Us – Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
CONTACT:
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Releases New Report on the Global Primary Biliary Cholangitis (PBC) Treatment Market here
News-ID: 564837 • Views: …
More Releases from Future Market Insights

Electronic Tongue Market will grow USD 774.2 million by 2035, at a 4.5% CAGR, fu …
The global electronic tongue market is advancing rapidly, poised to reach USD 497.9 million in 2025 and climb to USD 774.2 million by 2035, growing at a promising 4.5% CAGR. The increasing demand for precision diagnostics, pharmaceutical quality control, and personalized medicine is driving this technological surge, positioning the electronic tongue as a futuristic, non-invasive diagnostic instrument in healthcare and pharmaceuticals.
Electronic tongues, by design, mimic human sensory functions through an…

ESD Tapes and Labels market will expand USD 4,253.3 million by 2035, growing at …
The global market for ESD (electrostatic discharge) tapes and labels is entering a new decade of expansion driven by technological innovation, the rise of miniaturized electronics, and heightened quality standards in manufacturing. Valued at USD 2,738.8 million in 2025, the market is expected to reach USD 4,253.3 million by 2035, expanding at a steady 4.5% CAGR. This reflects a world increasingly dependent on efficient anti-static solutions that ensure the protection…

Catalase Market will rise USD 575.9 million by 2035 at 3.1% CAGR, driven by sust …
The global market for catalase is preparing for steady long-term expansion, driven by green chemistry, renewable sourcing, and biotechnology-driven production upgrades. Projected to reach USD 424.5 million in 2025 and USD 575.9 million by 2035, the industry's 3.1% CAGR reflects its broadening influence across critical sectors including food and beverages, pharmaceuticals, textiles, and personal care. With growing concerns about sustainability, efficiency, and safety, catalase is emerging as a vital biocatalyst…

Quillaia Extract market is set to reach USD 1,826.9M by 2035 at 5.8% CAGR fueled …
The global Quillaia extract market is entering a period of unprecedented growth, reflecting the world's shift toward natural, functional, and nutrient-rich ingredients. Projected to increase from USD 1,039.6 million in 2025 to USD 1,826.9 million by 2035 at a robust 5.8% CAGR, the industry's future is shaped by consumer demand for healthier, eco-friendly products and manufacturers' determination to stay ahead through innovation, expansion, and diversification.
Over the past few years, Quillaia…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…